AUS
NZ
UK
CA
USA
IND
In a strategic move aimed at optimizing financial performance, Moderna (NASDAQ:MRNA) has announced plans to cut its research and development (R&D) spending by 20% for the years 2025 to 2028. This reduction will bring the total R&D expenditure down to $16 billion over the period. For 2024, the company expects to spend around $4.8 billion on R&D efforts, a significant allocation as it shifts focus towards long-term sustainability.
2025 Revenue Forecasts Revised
The biotech company has also revised its revenue forecast for 2025, projecting earnings between $2.5 billion and $3.5 billion. This comes in lower than the $3.87 billion anticipated by analysts surveyed by FactSet. The more conservative revenue outlook reflects adjustments made as Moderna continues to navigate the evolving post-pandemic environment and the changing demand for its Covid-19 vaccine.
Focus on Operating Cash Break-Even in 2028
Moderna emphasized that the cutbacks in R&D spending are part of a broader effort to achieve operational sustainability. By tightening its spending, the company aims to break even on an operating cash basis by 2028. Executives assured stakeholders that Moderna has sufficient cash reserves to fund its growth initiatives through 2028 without needing to raise additional equity.
Diversifying Beyond Covid-19 Vaccines
In line with its longer-term strategic goals, Moderna is planning for the approval of 10 new products over the next three years. This expansion into new areas will help diversify its portfolio and reduce reliance on the revenue generated from its Covid-19 vaccine. The shift marks a critical turning point as the company adapts to declining vaccine demand and seeks new growth avenues through its mRNA technology platform.
Stock Impact Following Lowered Sales Guidance
Moderna's stock took a hit just over a month ago when the company slashed its 2024 net sales guidance, reflecting the broader challenges facing the Covid-19 vaccine market.
